Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone781-674-4400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$36.78 million
Profitability
Miscellaneous
Employees294
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Agenus (NASDAQ:AGEN) Frequently Asked Questions
What is Agenus' stock symbol?
Agenus trades on the NASDAQ under the ticker symbol "AGEN."
How were Agenus' earnings last quarter?
Agenus Inc (NASDAQ:AGEN) released its earnings results on Thursday, August, 8th. The biotechnology company reported ($0.38) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.33) by $0.05. The biotechnology company had revenue of $15.72 million for the quarter, compared to analysts' expectations of $5.37 million. View Agenus' Earnings History.
When is Agenus' next earnings date?
What price target have analysts set for AGEN?
1 analysts have issued 1 year price targets for Agenus' stock. Their forecasts range from $5.00 to $5.00. On average, they anticipate Agenus' share price to reach $5.00 in the next year. This suggests a possible upside of 79.2% from the stock's current price. View Analyst Price Targets for Agenus.
What is the consensus analysts' recommendation for Agenus?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agenus.
Has Agenus been receiving favorable news coverage?
News articles about AGEN stock have been trending positive on Sunday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Agenus earned a news impact score of 2.5 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View News Stories for Agenus.
Are investors shorting Agenus?
Agenus saw a increase in short interest in July. As of July 15th, there was short interest totalling 12,152,800 shares, an increase of 6.1% from the June 15th total of 11,454,900 shares. Based on an average daily trading volume, of 998,800 shares, the short-interest ratio is currently 12.2 days. Currently, 12.3% of the company's stock are short sold. View Agenus' Current Options Chain.
Who are some of Agenus' key competitors?
Some companies that are related to Agenus include Coherus Biosciences (CHRS), Audentes Therapeutics (BOLD), Sangamo Therapeutics (SGMO), Regenxbio (RGNX), Editas Medicine (EDIT), Momenta Pharmaceuticals (MNTA), Fate Therapeutics (FATE), Orchard Therapeutics (ORTX), Aerie Pharmaceuticals (AERI), Alector (ALEC), Twist Bioscience (TWST), NanoString Technologies (NSTG), BAVARIAN NORDIC/S (BVNRY), Rubius Therapeutics (RUBY) and Vericel (VCEL).
What other stocks do shareholders of Agenus own?
Who are Agenus' key executives?
Agenus' management team includes the folowing people:
- Dr. Garo H. Armen, Founder, Exec. Chairman & CEO (Age 66)
- Dr. Jennifer Buell, Chief Operating Officer
- Dr. Alexander R. Duncan, CTO & Head of Research (Age 57)
- Dr. Christian Cortis, Chief Strategy Officer & Head of Fin. (Age 51)
- Ms. Christine M. Klaskin, Principal Accounting Officer & VP of Fin. (Age 53)
Who are Agenus' major shareholders?
Agenus' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.92%), Vanguard Group Inc. (4.13%), D. E. Shaw & Co. Inc. (2.17%), Artal Group S.A. (1.86%), Oracle Investment Management Inc. (1.03%) and Northern Trust Corp (0.87%). Company insiders that own Agenus stock include Alex Duncan, Christine M Klaskin, Garo H Armen and Karen Valentine. View Institutional Ownership Trends for Agenus.
Which major investors are selling Agenus stock?
AGEN stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Morgan Stanley, Artal Group S.A., Bank of America Corp DE, Price T Rowe Associates Inc. MD, BNP Paribas Arbitrage SA, Bank of New York Mellon Corp and Virtus ETF Advisers LLC. View Insider Buying and Selling for Agenus.
Which major investors are buying Agenus stock?
AGEN stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Alps Advisors Inc., Strs Ohio, Chicago Equity Partners LLC, Marshall Wace LLP, Charles Schwab Investment Management Inc. and Acadian Asset Management LLC. View Insider Buying and Selling for Agenus.
How do I buy shares of Agenus?
Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Agenus' stock price today?
One share of AGEN stock can currently be purchased for approximately $2.79.
How big of a company is Agenus?
Agenus has a market capitalization of $383.09 million and generates $36.78 million in revenue each year. The biotechnology company earns $-159,690,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. Agenus employs 294 workers across the globe.View Additional Information About Agenus.
What is Agenus' official website?
How can I contact Agenus?
Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]
MarketBeat Community Rating for Agenus (NASDAQ AGEN)
MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe AGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
